Incyte (INCY) Tops Q1 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2019 7:00 AM EDTTotal revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019 Jakafi® (ruxolitinib) revenues of $376 million in Q1 2019 (+20% vs Q1 2018), reaffirming full year 2019 revenue guidance range of $1.58-1.65 billion Primary endpoint met in Phase 2 trial of ruxolitinib cream for the treatment of vitiligo; preparations now underway for Phase 3 development Decision taken to no longer participate in the co-funding of the development of baricitinib
Conference Call and... More
